PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of schbulOxford JournalsContact UsMy BasketMy AccountSchizophrenia BulletinAbout this JournalContact this JournalSubscriptionsCurrent IssueArchiveSearch
 
Schizophr Bull. 2012 March; 38(2): 304–315.
Published online 2010 July 11. doi:  10.1093/schbul/sbq077
PMCID: PMC3283161

Neurocognitive Predictors of Objective and Subjective Quality of Life in Individuals With Schizophrenia: A Meta-Analytic Investigation

Abstract

Quality of life (QOL) has been recognized as a crucial domain of outcome in schizophrenia treatment, and yet its determinants are not well understood. Recent meta-analyses suggest that symptoms have only a modest relationship to QOL (Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225–1237). Individuals with schizophrenia show 1–2 SD deficits on measures of elementary neurocognition, and links between these deficits and objective measures of community functioning (eg, employment and independent living) are well established. While objective measures of community functioning and measures of QOL would appear to be closely related, studies investigating the ability of neurocognitive variables to predict QOL in individuals with schizophrenia have yielded conflicting results. One potential explanation for opposing findings in the schizophrenia literature is the interchangeable use of objective and subjective indices of QOL. This study used quantitative methods of meta-analysis to clarify the relationship between neurocognitive determinants of objective QOL (ie, observable, clinician-rated) and subjective QOL (ie, patient satisfaction) separately in individuals with schizophrenia. A total of 20 studies (10 objective and 10 subjective) consisting of 1615 clients were aggregated from relevant databases. Weighted effect size analysis revealed that there were small–moderate relationships (d ≤ 0.55) between crystallized verbal ability, working memory verbal list learning, processing speed, and executive function and objective indices of QOL. In contrast, results revealed either nonsignificant or inverse relationships for the vast majority of neurocognitive measures and measures of subjective QOL. Moderating variables and implications for future research and treatment development are discussed.

Keywords: outcome, cognition, psychotic illness

Introduction

With the emergence of more effective pharmacologic management of acute psychiatric symptoms in schizophrenia over the past 20 years, increasing attention has been paid to the development of interventions targeted at improving the long-term functional and subjective outcomes for people with the illness. One of the dominant approaches to measurement of outcome in the schizophrenia literature has been the use of scales designed to assess the construct of quality of life (QOL2). Although there is not a single definition of QOL, most agree that it is a multidimensional construct that includes a person’s subjective sense of well-being, functional status, and access to resources and opportunities.3 Thus, knowledge of the determinants of QOL in individuals with schizophrenia is of key importance in tailoring effective interventions to improve the lives of people with the disease. Despite this fact, an understanding of determinants of QOL in schizophrenia remains elusive. An obvious candidate would be persistent psychiatric symptoms. However, a recent meta-analysis by Eack and Newhill1 found only small negative relationships between levels of psychiatric symptoms and QOL, with general psychopathology (eg, anxiety and depression) showing the strongest association across all QOL domains. Therefore, although psychiatric symptoms clearly influence QOL in individuals with schizophrenia, they explain only a modest proportion of variance in QOL.

Neurocognitive deficits are a core aspect of schizophrenia.4 Individuals diagnosed with schizophrenia consistently show 1–2 SD deficits on measures of speed of processing, attention/vigilance, working memory, verbal learning and memory, visual learning and memory, reasoning, and problem solving.5 Particular significance has been attached to these deficits as many have been moderately associated with impaired community functioning (eg, living or vocational status) in individuals with schizophrenia, both cross-sectionally and longitudinally.68 Moreover, these deficits may actually better account for the diversity of community outcomes in schizophrenia than positive or negative symptoms.9

While neurocognitive deficits have been linked to impairment on measures of objective measures of community function, results of studies examining the relationship between neurocognition and QOL in patients with schizophrenia have been mixed. Some studies have demonstrated a positive relationship between neurocognitive domains and aspects of QOL,10,11 whereas others show an inverse relationship.12,13 In other cases, the data revealed no relationship between neurocognitive deficits and QOL.14,15 For example, the same measure of executive function, the Wisconsin Card Sorting Test (WCST) perseverative error (PE) score, has been linked to QOL when measured by the Heinrichs–Carpenter Quality of Life Scale (QLS),10 an objective measure of QOL, but was shown to be unrelated to QOL in a second study that selected the World Health Organization Quality of Life Scale-Brief (WHOQOL-BREF15), a subjective measure of QOL.

Given: (1) the importance of understanding determinants of QOL in schizophrenia for developing effective clinical treatment interventions that would improve patient functional and subjective well-being, (2) the growing literature on neurocognitive predictors of QOL in patients with schizophrenia over the past 10 years, and (3) the highly contradictory findings across studies, a quantitative meta-analysis of the literature was warranted. The present study was formulated with the hypothesis that the discordance in findings regarding neurocognition and QOL might be explained by the considerable variance in types of QOL measures used by different research teams. Indeed, a review of the general medical literature, Gill and Feinstein16 found 159 different “QOL” measures used in the 75 studies they evaluated.

One approach to classifying measures of QOL is to view global well-being as a composite of at least somewhat independent dimensions of objective QOL indicators and subjective QOL indicators as well as personal characteristics.17 By this view, objective QOL refers to observable life conditions of the client and may be assessed through clinician ratings or client self-report, but in either case, the patient’s current or recent functional status is under review. In this regard, the construct of objective QOL has considerable overlap with more general constructs and measures of community/social functioning. Subjective QOL, according to this model, specifically refers to client satisfaction across parallel life domains. For example, the domain of social relations might be measured by asking questions about the frequency of the patient’s social contacts, eg, “How often do you spend time with close friends?” In contrast, subjective QOL for social relations measures patient satisfaction, asking for a subjective assessment of quality of the patient’s interactions with others, eg, “How do you feel about the amount of time you spend with other people?” (eg, Quality of Life Interview [QOLI]17).

To our knowledge, there have been no systematic literature analyses examining the relationship between neurocognition and QOL in patients with schizophrenia. We sought to use quantitative meta-analytic methods to: (1) determine whether there was a differential relationship between neurocognition and objective and subjective QOL in individuals with schizophrenia, (2) estimate the overall magnitude of these relationships, and (3) examine variables that moderate the relationship between neurocognition and subjective and objective QOL (eg, age, illness duration, and symptoms). We predicted: (1) because objective QOL indicators overlap considerably with measures of community functioning, we would replicate previous findings6,7 and uncover small–medium effect sizes between neurocognitive measures and objective QOL; (2) in contrast, we predicted a negligible relationship between neurocognition and subjective QOL, as previous studies in both schizophrenia and nonpsychiatric populations have shown a nonsignificant relationship between general neurocognitive functioning and subjective QOL instruments.15,1820

Methods

Literature Search

We conducted parallel literature searches in the PUBMED and PSYCINFO databases for all peer-reviewed, English-language articles published between January 01, 1980 and January 10, 2009 using the search terms (“cognition” AND “schizophrenia” AND “QOL”) and (“cognition” AND “schizophrenia” AND “social functioning”) and (“severe mental illness” AND “QOL”). The year 1980 was selected as the cutoff in light of the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Third Edition for more reliable diagnostic criteria for schizophrenia illness.21 The reference sections of articles located from both searches were studied for relevant citations.

Inclusion Criteria

General study inclusion criteria were as follows: (1) at least one-third participants with schizophrenia or schizoaffective disorder, (2) use of standard neuropsychological test battery, (3) cross-sectional relationship without treatment intervention, (4) use of either an objective and/or subjective QOL measure that relied on client self-report, measured multiple life domains, and that had been validated for use in schizophrenia, and (5) study statistics were convertible to effect size d (eg, Pearson r, beta regression coefficients).

These database searches yielded 518 potential studies. The majority of these studies were excluded because they did not use a standard neuropsychological test battery or a dedicated QOL instrument that met criteria for inclusion or did not study individuals with schizophrenia. Others measured neurocognitive functioning and QOL but did not present data relating the 2 variables. In addition, studies not using a cross-sectional paradigm were excluded. However, longitudinal studies that presented baseline correlations between neurocognitive measures and QOL were included. Upon review, 27 studies met our study inclusion criteria. Of these, 11 authors who did not publish correlation coefficients between individual neurocognitive measures and total QOL were solicited for additional data. In total, 20 studies (10 objective and 10 subjective) were included in our analysis. See table 1 for detailed study descriptions.

Table 1.
Neurocognition and QOL in Schizophrenia

Measure Selection

Neurocognitive Measures.

To ensure stability of findings, neurocognitive measures were selected for inclusion in this meta-analysis based on their use in at least 3 different studies. A total of 14 different neurocognitive measures were selected (see table 2). The following neurocognitive domains were included for analysis: crystallized verbal ability, fluency, vigilance, working memory, prose recall, list learning, processing speed, and executive function. Effect sizes were calculated and aggregated from individual cognitive tests with consistent outcome measures to minimize the combination of effect sizes from different tests and different outcome measures from the same test that could be tapping different neurocognitive constructs. For example, performance on the WCST is measured with multiple scores, most often either categories achieved (CAT) or number of PEs. These 2 outcome measures, while clearly related and from the same test, measure different presumed underlying constructs, concept formation and flexibility on the one hand, and set-shifting on the other. Thus, we examined these scores separately in this analysis.

Table 2.
Neurocognitive Measures Included in the Meta-Analysis

In light of their high degree of test similarity, outcome measures were combined across each of 3 verbal list-learning measures, the Hopkins Verbal Learning Test (HVLT), Rey Auditory Verbal Learning Test (RAVLT), and the California Verbal Learning Test (CVLT). Results from Logical Memory subtests from the Wechsler Memory Scale (WMS) and WMS-Revised were also combined, as were results from the paper-and-pencil and computerized versions of the WCST.

QOL Measures.

In order to be considered for inclusion in the meta-analysis both subjective and objective QOL measures had to be: (1) validated in samples of individuals with schizophrenia, (2) measure multiple life domains (eg, occupation, social interactions, and recreation/leisure etc.), and (3) rely on client self-report. Four objective QOL measures meeting these criteria were selected: (1) the Heinrichs–Carpenter QLS,34 (2) the Lehman QOLI17 objective subscale, (3) the Strauss–Carpenter Specific Levels of Function scale (SLOF35), and (4) the Sickness Impact Profile (SIP36). There are differences among the scales chosen in that SIP uses a written questionnaire completed by the patient, whereas the QLS, QOLI, and SLOF use a rated interview format. In addition, the QLS, QOLI, SLOF, and SIP all assess multiple patient life domains; they include questions specifically related to occupation, social interactions, recreation/leisure, and emotional status. Other scales that measured patient’s multidimensional life function but did not rely on patient self-report were excluded (eg, Global Assessment of Function). It should be noted that some researchers have categorized the SIP as a “subjective” measure of QOL because it utilizes patient self-report.14,37,38 For the current study, however, we classified the measure as an objective index in light of its focus on objective life conditions and not on subjective ratings of life satisfaction.

Three subjective QOL measures met our criteria: (1) WHOQOL-BREF Version39, (2) the Lehman QOLI17 subjective subscale, and (3) the Satisfaction with Life Scale (SWL40). All 3 of these scales also rely on self-report of the patient, 2 in the form of a written questionnaire (WHOQOL-BREF and SWL), and 1 in the form of a structured interview (QOLI). All included scales assess multiple life domains; however, they are distinct from the objective scales in that they specifically measure the patient’s subjective satisfaction with their life conditions, as opposed to assessing objective functional status. We note that scales that combined objective QOL and subjective QOL questions in the same overall measure were excluded due to the comparative nature of the present study (eg, Lancashire Quality of Life Profile41).

Data Analysis

The software program “DSTAT v. 1.11”42 was used to calculate effect sizes and to carry out subsequent homogeneity and moderator variable analyses. The unit of analysis in a meta-analysis is the effect size (d). For purposes of the present study, the d score was always defined as the strength of the relationship between each neurocognitive variable and objective or subjective QOL measure expressed in SD units. For 14 studies, we converted r into Cohen d values. One study reported beta coefficients from a multiple regression not correlation coefficients. In this study, we converted beta values into an approximate r for meta-analysis using the method outlined by Peterson and Brown.43 Nonsignificant results from 5 studies lacking supporting statistical information were coded as an effect size of zero.44 Four studies did not present correlations for total QOL score but instead reported correlations of specific neurocognitive domains with specific QOL domains. For these studies, as we predicted a positive relationship between neurocognition and objective QOL, we conservatively coded the lowest summary domain correlation for studies of objective QOL. In contrast, because we predicted a negligible relationship between neurocognition and subjective QOL, for subjective QOL studies, we coded the highest domain correlation. Effects were categorized as small (d < 0.5), medium large (d = 0.5–0.8), or large (d > 0.845). All effect sizes were expressed in a way such that positive values indicate better performance on neurocognitive tests.

Individual values of d were thereafter combined across studies and weighted according to their variance using a fixed-effects model. Potential differences in effect size between studies were analyzed using the method of Hedges and Olkin.46 This procedure computes mean weighted effect sizes and 95% CIs for each variable subset and allows for the testing of the influence of each individual factor on the overall results using the Q statistic. To assess stability of underlying effects, we used a test for heterogeneity QT, which is based on the sum of squares of the individual effect sizes around the mean when each square is weighted by the inverse of the estimated variance of the effect size. Q has an asymptotic χ2 distribution and is analogous to the ANOVA. Studies were evaluated for within-group differences (QW) and between-group differences (QB) following the same model.

To partially address the “file drawer” or publication bias problem in meta-analytic investigations, in which null results in a research area are collected but not reported in the literature, we calculated a fail-safe N (NFS) for each class of outcome variable by the method of Orwin.47 This measure provides an estimate of the number of studies with null results that would be needed to reduce the obtained mean effect size to a nonsignificant level. In the absence of a universally accepted significance level for effect sizes, we considered an effect size of 0.05 nonsignificant.

Moderator Analyses

Moderator analyses were conducted when the test for heterogeneity (Qw) for a specific neuropsychological measure was significant. Results are not reported for nonsignificant moderator analyses. Study characteristics hypothesized to moderate the relationship of neurocognition and QOL were: treatment setting (inpatient, outpatient, or mixed), symptomatology (Positive and Negative Syndrome Scale48), sample age, gender (% male), illness duration, age of onset, number of hospitalizations, average daily antipsychotic medication dose in chlorpromazine (CPZ) equivalents, and type of QOL measure. In addition, we included 2 study quality characteristics in our moderator analysis (1) confirmatory Structured Clinical Interview for DSM-IV diagnostic interviews49 and (2) QOL raters blind to neuropsychological test results. All study characteristics were coded independently by 2 raters (A.W.T) and (M.M.K.) in a subsample of 40% of studies to ensure reliability of extraction of study characteristics. Inter-rater concordance for coding was calculated to be 96%. Continuous moderator variables (eg, participant age and illness duration) were analyzed with a continuous model50 with a z test for significance of model fit. Mean weighted effect sizes were directly compared for relationships between neurocognition and objective QOL and neurocognition and subjective QOL. These effect size comparisons were made only between independent samples of clients administered neurocognitive measures and objective or subjective QOL measures. While alpha was set at .05 for the study as a whole, given the high number of moderator analyses and corresponding inflation in risk for alpha error, we used a reduced alpha level of .01 for these specific comparisons.

Results

Study Characteristics

A summary of sample characteristics of the 10 objective QOL studies the 10 subjective QOL studies that met inclusion criteria for the meta-analysis are presented in table 3.

Table 3.
Sample Characteristics

Neurocognitive Deficits and Objective QOL

As can be seen in table 4, the majority of neurocognitive domains were positively correlated with objective QOL. Small effect sizes were found for the relationship between crystallized verbal ability (Wechsler Adult Intelligence Scale [WAIS]-Vocabulary, d = 0.34, 95% CI: 0.13/0.55), working memory (WAIS-Digit Span, d = 0.26, 95% CI: 0.11/0.41; WAIS-Letter–Number Sequencing, d = 0.17, 95% CI: 0.06/0.28), verbal list learning (CVLT/HVLT/RAVLT immediate, d = 0.37, 95% CI: 0.24/0.51; CVLT/HVLT/RAVLT delayed, d = 0.13, CI: 0.01/0.25), processing speed (WAIS-Digit Symbol, d = 0.23, 95% CI: 0.10/0.36), and objective QOL. Executive function was found to have a small-medium effect size relationship to objective QOL (WCST-PE, d = 0.28, 95% CI: 0.14/0.41; WCST-CAT, d = 0.55, 95% CI: 0.38/0.72). Attention and prose recall were the only neurocognitive domains that were not significantly correlated (Ps > .08) with objective QOL.

Table 4.
Estimated Effect Sizes of the Relationship between Neurocognition and Objective QOL

Heterogeneity measures suggested that the overall weighted mean effect of the relationships between objective QOL and processing speed, verbal list learning, working memory (only the Letter–Number Sequencing test), and executive function (only the PE score from the WCST) were not stable. Moderator analyses of processing speed revealed that greater age (Z = −3.17, P = .002), more years of education (Z = −2.8, P = .005), and a greater number of hospitalizations (Z = −3.08, P = .002) attenuated the relationship between processing speed and objective QOL. In addition, moderator analyses revealed that greater years of education (z = −2.86, P = .004) attenuated the relationship between list learning (immediate recall) and objective QOL. Greater daily antipsychotic medication dose (Z = −2.70, P = .007) and more negative symptoms (Z = −2.82, P = .005) attenuated the relationship between executive function (WCST-PE) and objective QOL. Longer duration of illness correlated with larger effect sizes between both measures of list learning (Z = 2.63, P = .008) and executive function and objective QOL (Z = 0.284, P = .004). Greater percentage of males (Z = −3.57, P = .000) and greater mean sample age of onset (Z = −3.10, P = .002) attenuated the relationship between working memory (Letter–Number Sequencing) and objective QOL.

Neurocognitive Deficits and Subjective QOL

As can be seen in table 5, the majority of neurocognitive domains were not significantly correlated with subjective QOL, with the exception of crystallized verbal ability and processing speed, which were negatively correlated with subjective QOL and letter fluency, which was positively correlated with subjective QOL. Small effect sizes were revealed for verbal IQ (WAIS-vocabulary, d = −0.29, 95% CI: −0.49/−0.10), processing speed (WAIS-digit symbol, d = −0.19, 95% CI: −0.36/−0.02), and letter fluency (d = 0.26, 95% CI: 0.09/0.43). Measures of attention, working memory, verbal list learning, prose recall, and executive function were not significantly correlated with subjective QOL (all Ps > .06).

Table 5.
Estimated Effect Sizes of the Relationship between Neurocognition and Subjective QOL

Heterogeneity measures suggested that the overall weighted mean effect of the relationships between subjective QOL and crystallized verbal ability, processing speed, and letter fluency were not stable. Moderator analyses of crystallized verbal ability revealed that greater age was related to smaller mean effect sizes (Z = −3.85, P = .001). Treatment setting (inpatient, outpatient, or mixed) also significantly moderated the relationship between crystallized verbal ability and subjective QOL (inpatient d = 0.00, outpatient d = −0.52, QB = 6.83, P = .009), as did QOL measure (WHOQOL d = 0.00, QOLI d = −0.52, QB = 6.83, P = .009). Moderator analyses also revealed that greater percentage of males was related to a stronger relationship between processing speed and subjective QOL (Z = 2.89, P = .003). The relationship of letter fluency to subjective QOL was moderated by treatment setting (inpatient d = 0.84, outpatient d = −0.19, QB = 26.97, P = .000) and QOL measure (WHOQOL d = 0.53, QOLI d = −0.28, QB = 19.35, P = .000).

Comparison of Relationship of Neurocognitive Measures to Objective vs Subjective Measures of QOL

In addition, we made direct comparisons between relationships of the 2 QOL measure types (objective vs subjective) to each neurocognitive domain (see figure 1). One study that administered subjective and objective measures of QOL to the same participants was excluded as effect sizes across objective and subjective QOL indices from this study were not independent.27 Results revealed between-group differences in the relationship of neurocognition and subjective and objective QOL for crystallized verbal ability (WAIS-Vocabulary, QB = 13.86, P = .000), immediate prose recall (LM1, QB = 6.43, P = .011), list learning (CVLT/HVLT/RAVLT immediate QB = 5.66, P = .017), processing speed (WAIS-Digit Symbol, QB = 4.56, P = .033), and executive function (WCST-PE: QB = 5.42, P = .02; WCST-CAT: QB = 11.55, P = .020). The relationship between working memory (digit span) and delayed prose recall was not different for subjective and objective QOL.

Fig. 1.
Overall Effect Size Comparison (±95% CI) of the Relationship between Standardized Measures of Neurocognition and Subjective and Objective Quality of Life in Individuals with Schizophrenia. *P < .05.

File-Drawer Analyses

We sought to determine the extent to which our findings could be influenced by unpublished studies “the file-drawer problem” of nonsignificant effects. As shown in table 4, for objective QOL, there would need to be 17 unpublished studies of negative findings for crystallized verbal ability to be unrelated to QOL, 17 and 10 for attention (digit span and letter–number sequencing, respectively), 26 and 5 for list learning and memory (CVLT/HVLT/RAVLT-immediate and delayed, respectively), 18 for processing speed, and 23 and 30 for executive function (WCST-PE and -CAT, respectively). As shown in table 5, for subjective QOL, there would need to be 14 unpublished studies of negative findings for crystallized verbal ability to be unrelated to QOL, 21 for letter fluency, and 11 for processing speed.

Discussion

This is the first meta-analytic study to directly compare the pattern of relationships between elementary neurocognitive domains and subjective and objective measures of QOL. Our results revealed 3 major findings. First, consistent with our hypotheses, we found a disparity between the relationship of neurocognitive deficits to measures of subjective QOL and neurocognitive deficits and objective QOL in individuals with schizophrenia. With a few exceptions, neurocognitive measures were positively correlated with objective QOL but either unrelated or negatively correlated with subjective QOL. More specifically, direct comparisons between studies using subjective vs objective QOL measures showed that the neurocognitive domains of crystallized verbal ability, immediate prose recall, list learning, processing speed, and executive function were differentially related to subjective and objective QOL.

Second, we found positive relationships between measures of crystallized verbal ability, working memory, verbal list learning, and processing speed and objective QOL that were all in the small (d = 0.17–0.34) effect size range, and relationships between measures of executive function and objective QOL were in the small–medium (d = 0.28–0.55) effect size range. These results are consonant with our hypotheses and are consistent with several previous reviews and meta-analyses that have found measures of working memory, verbal memory, and executive function are related to a range of measures of functional outcome in people with schizophrenia in both cross-sectional and longitudinal designs.68 Attention was not related to objective QOL in our study. This finding is also generally consistent with previous studies of neurocognition and functional outcome, which suggest that measures of attention are more strongly associated with performance-based measures of skill acquisition and social problem solving than measures of objective community functioning that overlap with the measures of objective QOL selected for the current study.6

There is considerable face validity to the assertion that individuals with higher verbal IQ, verbal memory, executive function, and processing speed will be more likely to perform better vocationally, maintain larger social networks, and live independently. However, it is important to note that the effect sizes for the relationship between neurocognitive deficits and objective QOL were generally small, suggesting that there are likely many other individual and social determinants of objective QOL in addition to elementary neurocognition. Indeed, research over the past several years has suggested a variety of potential moderating variables between neurocognition and functional outcome, such as social cognition,51 learning potential,7 and negative symptoms.52 Already there is preliminary evidence that at least one measure of social cognition, facial affect recognition, moderates the relationship between neurocognitive deficits and objective QOL.53

Third, in contrast to the objective QOL findings, we found a largely nonsignificant relationship between neurocognitive variables and subjective QOL. Measures of attention, working memory, verbal memory, and executive function were not related to measures of subjective QOL. However, measures of crystallized verbal ability (d = −0.29) and processing speed (d = −0.19) were both negatively correlated with subjective QOL. Verbal fluency was the only measure found to be positively (d = 0.26) correlated with subjective QOL.

Moderator Analyses

Our moderator analyses for neurocognitive and objective QOL measures revealed that as the mean study sample age increased the relationship between processing speed (Digit Symbol) and objective QOL was attenuated. Similarly, as education increased, the relationships between list learning and processing speed and objective QOL weakened. A speculative explanation for these findings is that neurocognitive abilities have less of a direct effect on objective QOL in older and more educated samples as the clients in these samples have had more practice and acquired more compensatory skills to cope with persistent neurocognitive deficits than their younger, less-educated counterparts. In other words, the educational process may provide practice of processing speed and list learning skills serving to decrease heterogeneity between clients on these measures, making these findings relatively independent of the disease, whereas these cognitive skills may be more heterogeneous and reflect more about the illness for younger, less-educated people. In addition, there was little evidence that psychiatric symptoms influenced the relationship between neurocognition and objective or subjective QOL.

Differential Relationship between Neurocognitive Deficits and Objective and Subjective QOL

While the very different relationships between neurocognition and objective vs subjective QOL might appear paradoxical, they are consistent with a wealth of research that has revealed that objective QOL instruments that measure social and vocational status do not correlate with subjective QOL instruments that measures satisfaction with these same life domains.17,28 For example, Skantze et al54 in a sample of 66 schizophrenia outpatients found that objective standard of life scale scores, which included objective indicators of housing quality and current employment, did not significantly correlate with scores on their QLS, which measured participant satisfaction in the same life domains. Factor analyses of QOL assessment items have supported this view as well. Warner et al55 conducted a factor analysis of responses to the Lancashire Quality of Life Profile, a QOL instrument that measures both objective and subjective domains and found that objective QOL variables loaded separately from subjective satisfaction ratings. This dissociation in constructs supports the notion that objective QOL and subjective QOL could have different sets of predictors in individuals with schizophrenia.

One potential explanation for the inverse relationship between domains of neurocognition and subjective QOL is that those individuals with stronger cognitive abilities may have greater insight into their illness and functional disability, enabling negative social comparison and thus lower life satisfaction.27,30,56 Studies have shown that schizophrenia patients with better cognitive abilities had more severe depression57 and greater insight into their illness.58 Additional research that examines insight into illness as a potential moderator of the relationship between neurocognition and subjective QOL will prove helpful in elucidating this relationship.

Limitations

Several caveats to the current studies should be mentioned: (1) This is the first meta-analysis to date of a new and rapidly growing research area investigating the relationship between neurocognition and subjective and objective QOL, and thus, we had a relatively small number of studies (k = 20). Thus, these findings are preliminary and will need to be replicated with larger numbers of studies employing these same neurocognitive measures and QOL indices. (2) As our “fail-safe N” analyses revealed, for a few of our reported relationships, there would need to be a very low number of unpublished studies with nonsignificant effects required to negate our findings (eg, NFS = 5 for the relationship of verbal list learning to objective measures of QOL). (3) Some elementary neurocognitive domains in the current analysis were not well-represented in terms of numbers of measures (eg, attention) included in the current analysis, and current findings will be strengthened with the addition of other neurocognitive measures designed to measure similar constructs. (4) Many of our moderator analyses were underpowered with 50% or less of included studies reporting sample duration of illness, negative and positive symptom scores, depression ratings, or medication dosage (see table 3). (5) We note that some of our strongest findings were unstable as measured by our heterogeneity statistic (eg, Vocabulary and subjective QOL). This instability may represent the grouping of very different sample types into the same heterogeneity analysis. (6) Important domains of neurocognition, such as nonverbal memory, were not included in the analysis as an insufficient number of extant studies employed these measures and thus the relationship of these measures to subjective and objective QOL remains unknown. (7) Several moderator analyses revealed that the type of QOL measure within the subjective QOL domains influenced the relationship of elementary neurocognition and QOL. These findings suggest that there was considerable between-measure variability in the assessment of the construct of subjective QOL.

Implications

Taken together, the markedly different pattern of relation between neurocognition and objective and subjective QOL has implications for the potential effects of intervention on cognitive deficits of individuals with schizophrenia. In light of the MATRICS initiative work toward the development of cognition-enhancing pharmacological agents and the growth of a range of behavioral interventions targeted directly at deficits in neurcognition,59,60 the differential relationship between neurocognition and objective and subjective QOL revealed in this study may be particularly pertinent. Our results confirm the positive link between neurocognition and objective QOL, suggesting that improving neurocognition could have a positive impact on objective measures of client functioning. However, because our results indicated that neurocognition was largely unrelated or for some neurocognitive domains even negatively related to subjective QOL, the current study emphasizes the need for clinical researchers to craft new interventions alongside those targeting cognition in order to ensure that integrated treatment interventions attend to individuals’ subjective life satisfaction in addition to improving objective QOL.

Funding

Howard Hughes Medical Institute Summer Fellowship Program (to A.W.T.); National Institute of Mental Health (K08 MH-69888); National Alliance for Research in Schizophrenia and Depression (Young Investigator Award; to M.M.K.).

Acknowledgments

We thank Drs J. Addington, E. Twamley, and D. Dickinson for providing raw data used in these analyses. The Authors have declared that there are no conflicts of interest in relation to the subject of this study.

References

1. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225–1237. [PMC free article] [PubMed]
2. Awad AG, Voruganti LP. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull. 2000;26:557–564. [PubMed]
3. Lehman AF. Measures of quality of life among persons with severe and persistent mental disorders. Soc Psychiatry Psychiatr Epidemiol. 1996;31(2):78–88. [PubMed]
4. Gold J, Harvey PD. Cognitive deficits in schizophrenia. The Psychiatr Clin North Am. 1993;16:295–312. [PubMed]
5. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445. [PubMed]
6. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330. [PubMed]
7. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119–136. [PubMed]
8. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41–51. [PubMed]
9. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1–21. [PubMed]
10. Addington J, Addington D. Social and cognitive functioning in psychosis. Schizophr Res. 2008;99(1–3):176–181. [PubMed]
11. Lysaker P, Davis L. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health Qual Life Outcomes. 2004;2(1):15. [PMC free article] [PubMed]
12. Corrigan PW, Buican B. The construct validity of subjective quality of life for the severely mentally ill. J Nerv Ment Dis. 1995;183:281–285. [PubMed]
13. Proteau A, Verdoux H, Briand C, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res. 2005;77:343–353. [PubMed]
14. Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci. 1997;22:235–243. [PMC free article] [PubMed]
15. Hofer A, Baumgartner S, Bodner T, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry. 2005;20:395–402. [PubMed]
16. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619–626. [PubMed]
17. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann. 1988;11:51–62.
18. Brissos S, Dias VV, Carita AI, Martinez-Arán A. Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res. 2008;160(1):55–62. [PubMed]
19. Chino B, Nemoto T, Fujii C, Mizuno M. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia. Psychiatry Clin Neurosci. 2009;63:521–528. [PubMed]
20. Bain GH, Lemmon H, Teunisse S, et al. Quality of Life in healthy old age: relationships with childhood IQ, minor psychological symptoms and optimism. Soc Psychiatry Psychiatr Epidemiol. 2003;38:632–636. [PubMed]
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-III. Washington, DC: American Psychiatric Press. 1987.
22. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull. 1999;25:173–182. [PubMed]
23. Dickinson D, Coursey RD. Independence and overlap among neurocognitive correlates of community functioning in schizophrenia. Schizophr Res. 2002;56(1–2):161–170. [PubMed]
24. Fiszdon JM, Choi J, Goulet J, Bell MD. Temporal relationship between change in cognition and change in functioning in schizophrenia. Schizophr Res. 2008;105(1–3):105–113. [PubMed]
25. Lipkovich I, Deberdt W, Csernansky JG, et al. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24-months of antipsychotic drug therapy. BMC Psychiatry. 2009;9:44. [PMC free article] [PubMed]
26. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:280–287. [PubMed]
27. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008;98:201–208. [PMC free article] [PubMed]
28. Savilla K, Kettler L, Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust N Z J Psychiatry. 2008;42:496–504. [PubMed]
29. Alptekin K, Akvardar Y, Akdede BB, et al. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:239–244. [PubMed]
30. Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull. 2001;27:697–708. [PubMed]
31. Dickerson F, Ringel NB, Parente F. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand. 1998;98(2):124–127. [PubMed]
32. Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int J Ment Health Nurs. 2004;13:282–291. [PubMed]
33. Smith TE, Hull JW, Goodman M, et al. The relative influence of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999;187(2):102–108. [PubMed]
34. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for assessing the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–396. [PubMed]
35. Strauss J, Carpenter WT. Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry. 1977;34(2):159–163. [PubMed]
36. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787–805. [PubMed]
37. Voruganti LN, Heslegrave RJ, Awad AG. Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry. 1997;43:854–855. [PubMed]
38. Sota TL, Heinrichs RW. Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neuroleptics. Compr Psychiatry. 2004;45:415–421. [PubMed]
39. WHO Group. The World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28:551–558. [PubMed]
40. Stein LI, Test MA. Alternatives to mental hospital treatment: I. Conceptual model treatment program and clinical evaluation. Arch Gen Psychiatry. 1980;37:392–397. [PubMed]
41. Oliver JP, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):76–83. [PubMed]
42. Johnson BT. DSTAT: Software for Meta-Analytic Reviews of Research Literature [computer program] Hillsdale, NJ: Erlbaum; 1993.
43. Peterson RA, Brown SP. On the use of beta coefficients in meta-analysis. J Appl Psychol. 2005;90(1):175–181. [PubMed]
44. Lipsey MW, Wilson DB. The way in which intervention studies have “personality” and why it is important to meta-analysis. Eval Health Prof. 2001;24:236–254. [PubMed]
45. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1977.
46. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York, NY: Academic Press; 1985.
47. Orwin RG. A fail-safe N for meta-analysis. J Educ Stat. 1983;8(2):157–159.
48. Kay SR, Fizszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull. 1987;13:261–276. [PubMed]
49. Spitzer R, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for the DSM-III-R. Washington, DC: American Psychiatric Press; 1990.
50. Rosenthal R. Meta-Analytic Procedures for Social Research. London, UK: Sage; 1986.
51. Penn DL, Sanna LJ, Roberts DL. Social cognition in schizophrenia: an overview. Schizophr Bull. 2008;34:408–411. [PMC free article] [PubMed]
52. Bowie CR, Leung WW, Reichenberg AA, et al. Predicting schizophrenia patients’ real world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63:505–511. [PMC free article] [PubMed]
53. Addington J, Saeedi H, Addington D. Facial affect recognition: a mediator between cognitive and social functioning in psychosis? Schizophr Res. 2006;85(1–3):142–150. [PubMed]
54. Skantze K, Malm U, Dencker SJ, May PR, Corrigan P. Comparison of quality of life with standard of living in schizophrenic out-patients. Br J Psychiatry. 1992;161:797–801. [PubMed]
55. Warner R, de Girolamo G, Belelli G, Bologna C, Fioritti A, Rosini G. The quality of life of people with schizophrenia in Boulder, Colorado, and Bologna, Italy. Schizophr Bull. 1998;24:559–568. [PubMed]
56. Karow A, Pajonk FG. Insight and quality of life in schizophrenia: recent findings and treatment implications. Curr Opin Psychiatry. 2006;19:637–641. [PubMed]
57. Bowie CR, Twamley EW, Anderson H, Halpern B, Patterson TL, Harvey PD. Self-assessment of functional status in schizophrenia. J Psychiatr Res. 2007;41:1012–1018. [PMC free article] [PubMed]
58. Subotnik KL, Nuechterlein KH, Irzhevsky V, Kitchen CM, Woo SM, Mintz J. Is unawareness of psychotic disorder a neurocognitive or psychological defensiveness problem? Schizophr Res. 2005;75(2–3):147–157. [PubMed]
59. Marder S. Initiatives to promote the discovery of drugs to improve cognition in severe mental illness. J Clin Psychiatry. 2006;67(7):e03. [PubMed]
60. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007;164:437–441. [PMC free article] [PubMed]

Articles from Schizophrenia Bulletin are provided here courtesy of Oxford University Press